Enhancement of immune response by combining immune checkpoint blockade and radiation in patients with recurrent / refractory malignant lymphoma (re-directing the immune system).

none0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•patients with refractory / recurrent malignant lymphoma eligible for immune checkpoint blockade therapy
•- aged 18 – 75 year
•- WHO score =2
•- adequate organ function
•- no prior treatment with checkpoint inhibitors
•- no non-infectious pneumonitis requiring steroids
•- not pregnant
•- patients of childbearing / reproductive potential should use 2 birth control methods
•- written informed consent

•- Not fit (mentally or physically) to undergo the proposed treatment.
•- Patients with connective tissue diseases (inflammatory myopathy (polymyositis and ermatomyositis), systemic lupus erythematosus, Sjögren syndrome, systemic sclerosis, antisynthetase syndrome, rheumatoid arthritis, severe psoriasis and mixed CTDs), vasculitis (granulomatosis with polyangiitis (Wegener’s granulomatosis), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome), severe Behçet disease, Takayasu arteritis, giant cell arteritis, Buerger disease, Kawasaki disease, polyarteritis nodosa, severe immunoglobulin A (IgA) vasculitis (Henoch–Schönlein purpura), severe cutaneous vasculitis, polymyalgia rheumatica, severe cryoglobulinaemia and undifferentiated systemic vasculitis) and other autoimmune diseases (primary biliary cirrhosis, severe autoimmune hepatitis, multiple sclerosis, severe antiphospholipid syndrome, myasthenia gravis, Guillain–Barré syndrome, inflammatory bowel disease, Miller–Fisher syndrome, Vogt–Koyanagi–Harada syndrome, eosinophilic fasciitis (Shulman syndrome), relapsing polychondritis and severe autoinflammatory diseases) ( Martins et al. 2019).
•- Sensory or motor peripheral neuropathy > grade 2.

发起方

none